Biocon says USFDA issued Complete Response Letter for insulin Glargine filed by Mylan

We remain committed to global standards of Quality & Compliance and are working closely with our partner and the regulator to complete these CAPAs to the satisfaction of the USFDA, the company said.

from India Infoline News Service https://ift.tt/2zKWHoL